Safety of Contrast Agent Use During Stress EchocardiographyA 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients
Sahar S. Abdelmoneim, MD, MSc*, ,
Mathieu Bernier, MD*,
Christopher G. Scott, MS ,
Abhijeet Dhoble, MD, MPH*,
Sue Ann C. Ness, RN*,
Mary E. Hagen, RDCS*,
Stuart Moir, MD*,
Robert B. McCully, MD*,
Patricia A. Pellikka, MD*,
Sharon L. Mulvagh, MD*,*
* Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
Division of Biostatistics, Mayo Clinic, Rochester, Minnesota
Division of Cardiovascular Diseases, Assiut University, Assiut, Egypt
View larger version (36K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Flowchart of the Study Population (November 1, 2003, Through December 31, 2007)
Patients in the contrast cohort received contrast agents during stress echocardiography (SE). Patients in the noncontrast cohort did not receive contrast agents during SE. Patients underwent SE with dobutamine or exercise. Miscellaneous indications were previous abnormal electrocardiograms and coronary calcification on cardiac electron beam computed tomography. CAD = coronary artery disease.
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Survival Free of Major Cardiovascular Events
Kaplan-Meier survival curves presenting survival free of major cardiovascular events including death and myocardial infarction over 4 years of follow-up for the dobutamine stress echocardiography (SE) and exercise SE subgroups. Patients in the contrast cohort received contrast agents during SE and patients in the noncontrast cohort did not. (A) Survival free of death. (B) Survival free of myocardial infarction. p values are reported from the unadjusted model. After adjustment for known confounders, no differences in the hazard ratios for the events were observed between the contrast and noncontrast cohorts.
|
|
|
